

## 1 **Appendix I: References for included and** 2 **cited studies**

- 3 Anon (2001) The Age-Related Eye Disease Study system for classifying age-related macular  
4 degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease  
5 Study Report Number 6 American Journal of Ophthalmology 132 (5) 668-681
- 6 Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled,  
7 clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for  
8 age-related macular degeneration and vision loss: AREDS report no. 8 Archives of  
9 Ophthalmology 119 (10) 1417
- 10 Ahmadi H, Taei R, Riazi-Esfahani M et al. (2011) Intravitreal bevacizumab versus  
11 combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular  
12 degeneration: six-month results of a randomized clinical trial Retina 31 1819-1826
- 13 Ajani UA, Christen WG, Manson JE et al. (1999) A prospective study of alcohol consumption  
14 and the risk of age-related macular degeneration Annals of epidemiology Ann Epidemiol 172-  
15 177
- 16 Almony A, Mansouri A, Shah GK et al. (2011) Efficacy of intravitreal bevacizumab after  
17 unresponsive treatment with intravitreal ranibizumab Can J Ophthalmol 46 182-185
- 18 Amoaku WM, Chakravarthy U, Gale R et al. (2015) Defining response to anti-VEGF  
19 therapies in neovascular AMD Eye 29 (6) 721-731
- 20 Arias L, Armada F, Donate J et al. (2009) Delay in treating age-related macular degeneration  
21 in Spain is associated with progressive vision loss Eye 23 (2) 326-333
- 22 Athanasakis K, Fragoulakis V, Tsiantou V et al. (2012) Cost-effectiveness analysis of  
23 ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best  
24 supportive care for the treatment of age-related macular degeneration in Greece Clinical  
25 therapeutics 34 (2) 446-456
- 26 Azzolini C, Torreggiani A, Eandi C et al. (2013) A teleconsultation network improves the  
27 efficacy of anti-VEGF therapy in retinal diseases Journal of Telemedicine & Telecare 19 (8)  
28 437-442
- 29 Barikian A, Mahfoud Z, Abdulaal M et al. (2015) Induction with intravitreal bevacizumab  
30 every two weeks in the management of neovascular age-related macular degeneration  
31 American Journal of Ophthalmology 159 (1) 131-137
- 32 Bartlett HE, Eperjesi F (2007) Effect of lutein and antioxidant dietary supplementation on  
33 contrast sensitivity in age-related macular disease: a randomized controlled trial European  
34 journal of clinical nutrition 61 (9) 1121-1127
- 35 Bashshur ZF, Schakal AR, El-Mollayess GM et al. (2011) Ranibizumab monotherapy versus  
36 single-session verteporfin photodynamic therapy combined with as-needed ranibizumab  
37 treatment for the management of neovascular age-related macular degeneration Retina  
38 (Philadelphia, Pa.) 31 636-644
- 39 Batioglu F, Demirel S, Ozmert E et al. (2015) Short-term outcomes of switching anti-VEGF  
40 agents in eyes with treatment-resistant wet AMD BMC ophthalmol 15 40-
- 41 Beatty S, Chakravarthy U, Nolan JM et al. (2013) Secondary outcomes in a clinical trial of  
42 carotenoids with coantioxidants versus placebo in early age-related macular degeneration  
43 Ophthalmology 120 (3) 600-606

- 1 Berg K, Pedersen TR, Sandvik L et al. (2015) Comparison of ranibizumab and bevacizumab  
2 for neovascular age-related macular degeneration according to LUCAS treat-and-extend  
3 protocol *Ophthalmology* 122 (1) 146-152
- 4 Berrow EJ, Bartlett HE, Eperjesi F et al. (2013) The effects of a lutein-based supplement on  
5 objective and subjective measures of retinal and visual function in eyes with age-related  
6 maculopathy□a randomised controlled trial *British journal of nutrition* 109 (11) 2008-2014
- 7 Birk T, Hickl S, Wahl HW et al. (2004) Development and pilot evaluation of a psychosocial  
8 intervention program for patients with age-related macular degeneration *The Gerontologist*  
9 44 (6) 836-843
- 10 Biswas P, Sengupta S, Choudhary R et al. (2011) Comparative role of intravitreal  
11 ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular  
12 degeneration *Indian journal of ophthalmology* 59 (3) 191-
- 13 Bittner AK, Torr-Brown S, Arnold E et al. (2014) Improved Adherence to Vision Self-  
14 monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-  
15 related Macular Degeneration during a Randomized Controlled Trial *Journal of clinical &*  
16 *experimental ophthalmology* 5 (1) 320-
- 17 Boekhoorn SS, Vingerling JR, Hofman A et al. (2008) Alcohol consumption and risk of aging  
18 macula disorder in a general population: the Rotterdam Study *Archives of ophthalmology*  
19 (Chicago, Ill.: 1960) 834-839
- 20 Boulanger-Scemama E, Querques G, About F et al. (2015) Ranibizumab for exudative age-  
21 related macular degeneration: A five year study of adherence to follow-up in a real-life setting  
22 *Journal Francais d Ophthalmologie* 38 620-627
- 23 Brader HS, Ying GS, Martin ER et al. (2011) New grading criteria allow for earlier detection  
24 of geographic atrophy in clinical trials *Investigative ophthalmology & visual science* 52 (12)  
25 9218-9225
- 26 Bressler SB, Maguire MG, Bressler NM et al. (1990) Relationship of drusen and  
27 abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular  
28 degeneration. The Macular Photocoagulation Study Group *Archives of ophthalmology*  
29 (Chicago, Ill.: 1960) 1442-1447
- 30 Bressler SB, Vitale S, Hawkins BS, et al. (1995) Laser to drusen trial-an assessment of  
31 short-term safety within a randomized, prospective controlled clinical-triallippincott-raven publ  
32 227 east washington square, philadelphia, PA 19106, p S255-S255.
- 33 Brody BL, Roch-Levecq AC, Gamst AC et al. (2002) Self-management of age-related  
34 macular degeneration and quality of life: a randomized controlled trial *Archives of*  
35 *Ophthalmology* 120 (11) 1477-1483
- 36 Brody BL, Roch-Levecq AC, Thomas RG et al. (2005) Self-management of age-related  
37 macular degeneration at the 6-month follow-up: a randomized controlled trial *Archives of*  
38 *Ophthalmology* 123 (1) 46-53
- 39 Brody BL, Roch-Levecq A-C, Kaplan RM et al. (2006) Age□Related Macular Degeneration:  
40 Self□Management and Reduction of Depressive Symptoms in a Randomized, Controlled  
41 Study *Journal of the American Geriatrics society* 54 (10) 1557-1562
- 42 Brown DM, Kaiser PK, Michels M et al. (2006) Ranibizumab versus verteporfin for  
43 neovascular age-related macular degeneration *New England Journal of Medicine* 355 (14)  
44 1432-1444

- 1 Brown DM, Michels M, Kaiser PK et al. (2009) Ranibizumab versus verteporfin photodynamic  
2 therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR  
3 study *Ophthalmology* 116 (1) 57-65
- 4 Brown GC, Sharma S, Brown MM et al. (2000) Utility values and age-related macular  
5 degeneration *Archives of Ophthalmology* 118 (1) 47-51
- 6 Brown GC, Brown MM, Brown HC et al. (2007) A value-based medicine comparison of  
7 interventions for subfoveal neovascular macular degeneration *Ophthalmology* 114 (6) 1170-  
8 1178
- 9 Brown MM, Brown GC, Sharma S et al. (2003) Quality of life associated with visual loss: a  
10 time tradeoff utility analysis comparison with medical health states *Ophthalmology* 110 (6)  
11 1076-1081
- 12 Buckle M, Donachie PH, Johnston RL (2016) Long-term outcomes of intravitreal ranibizumab  
13 for neovascular age-related macular degeneration in a well defined region of the UK *British*  
14 *Journal of Ophthalmology* 100 (2) 240-245
- 15 Bunce C, Xing W, Wormald R (2010) Causes of blind and partial sight certifications in  
16 England and Wales: April 2007-March 2008 *Eye* 24 (11) 1692-1699
- 17 Burton AE, Shaw RL, Gibson JM (2013) 'I'd like to know what causes it, you know, anything  
18 I've done?' Are we meeting the information and support needs of patients with macular  
19 degeneration? A qualitative study *BMJ Open* 3 (11) e003306
- 20 Burton AE, Shaw R, Gibson J (2013) Experiences of patients with age-related macular  
21 degeneration receiving anti-vascular endothelial growth factor therapy: A qualitative study  
22 *British Journal of Visual Impairment* 31 178-188
- 23 Busbee BG, Ho AC, Brown DM et al. (2013) Twelve-month efficacy and safety of 0.5 mg or  
24 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration  
25 *Ophthalmology* 120 (5) 1046-1056
- 26 Busija L, Pausenberger E, Haines TP et al. (2011) Adult measures of general health and  
27 health-related quality of life: Medical Outcomes Study Short Form 36 Item (SF 36) and Short  
28 Form 12 Item (SF12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact  
29 Profile (SIP), Medical Outcomes Study Short Form 6D (SF 6D), Health Utilities Index Mark 3  
30 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQOL)  
31 *Arthritis care & research* 63 (S11) S383-S412
- 32 Butt T, Crossland MD, West P et al. (2015) Simulation contact lenses for AMD health state  
33 utility values in NICE appraisals: a different reality *British Journal of Ophthalmology* 99 (4)  
34 540-544
- 35 Butt T, Lee A, Lee C et al. (2015) The cost-effectiveness of initiating ranibizumab therapy in  
36 eyes with neovascular AMD with good vision: an economic model using real-world outcomes  
37 *BMJ Open* 5 (5) e006535-
- 38 Cachulo L, Silva R, Fonseca P et al. (2010) Early markers of choroidal neovascularization in  
39 the fellow eye of patients with unilateral exudative age-related macular degeneration  
40 *Ophthalmologica* 225 (3) 144-149
- 41 CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related  
42 macular degeneration *N Engl J Med* 2011 (364) 1897-1908
- 43 Chakravarthy U, Wong TY, Fletcher A et al. (2010) Clinical risk factors for age-related  
44 macular degeneration: a systematic review and meta-analysis *BMC ophthalmology* 10 (1)  
45 31-

- 1 Chakravarthy U, Harding SP, Rogers CA et al. (2012) Ranibizumab versus bevacizumab to  
2 treat neovascular age-related macular degeneration: one-year findings from the IVAN  
3 randomized trial *Ophthalmology* 119 (7) 1399-1411
- 4 Chakravarthy U, Harding SP, Rogers CA et al. (2013) Alternative treatments to inhibit VEGF  
5 in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised  
6 controlled trial *The Lancet* 382 (9900) 1258-1267
- 7 Chakravarthy U, Harding SP, Rogers CA et al. (2015) A randomised controlled trial to assess  
8 the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in  
9 Age-related choroidal Neovascularisation (IVAN)
- 10 Chan C, Abraham P, Sarraf D et al. (2015) Earlier therapeutic effects associated with high  
11 dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in  
12 age-related macular degeneration *Eye (London, England)* 29 (1) 80-87
- 13 Chang AA, Li H, Broadhead GK et al. (2013) Intravitreal aflibercept for treatment-resistant  
14 neovascular age-related macular degeneration 41 52-
- 15 Chang AA, Li H, Broadhead GK et al. (2014) Intravitreal aflibercept for treatment-resistant  
16 neovascular age-related macular degeneration *Ophthalmology* 121 188-192
- 17 Chasan JE, Delaune B, Maa AY et al. (2014) Effect of a teleretinal screening program on eye  
18 care use and resources *JAMA Ophthalmology* 132 (9) 1045-1051
- 19 Cheong AM, Lovie-Kitchin JE, Bowers AR et al. (2005) Short-term in-office practice improves  
20 reading performance with stand magnifiers for people with AMD *Optometry and vision  
21 science* 82 (2) 114-127
- 22 Cheung CMG, Yanagi Y, Mohla A et al. (2016) Characterization and differentiation of  
23 polypoidal choroidal vasculopathy using swept source optical coherence tomography  
24 angiography *Retina* no-
- 25 Cheung CMG, Laude A, Wong W et al. (2015) Improved specificity of polypoidal choroidal  
26 vasculopathy diagnosis using a modified Everest criteria *Retina* 35 (7) 1375-1380
- 27 Chew EY, Sperduto RD, Milton RC et al. (2009) Risk of advanced age-related macular  
28 degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25  
29 *Ophthalmology* 297-303
- 30 Chew EY, Clemons TE, SanGiovanni JP et al. (2013) Age-Related Eye Disease Study 2  
31 Research Group. Lutein+ zeaxanthin and omega-3 fatty acids for age-related macular  
32 degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial  
33 *JAMA* 309 (19) 2005-2015
- 34 Chew EY, Clemons TE, Bressler SB et al. (2014) Randomized trial of a home monitoring  
35 system for early detection of choroidal neovascularization home monitoring of the Eye  
36 (HOME) study *Ophthalmology* 121 535-544
- 37 Chew EY, Clemons TE, SanGiovanni JP et al. (2014) Secondary analyses of the effects of  
38 lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3  
39 *JAMA Ophthalmology* 132 (2) 142-149
- 40 Chiu CJ, Milton RC, Klein R et al. (2007) Dietary carbohydrate and the progression of age-  
41 related macular degeneration: A prospective study from the Age-Related Eye Disease Study  
42 *American Journal of Clinical Nutrition* *Am.J.Clin.Nutr.* 1210-1218
- 43 Chiu CJ, Klein R, Milton RC et al. (2009) Does eating particular diets alter the risk of age-  
44 related macular degeneration in users of the Age-Related Eye Disease Study supplements?  
45 *British Journal of Ophthalmology* *Br.J.Ophthalmol.* 1241-1246

- 1 Cho H, Shah CP, Weber M et al. (2013) Aflibercept for exudative AMD with persistent fluid  
2 on ranibizumab and/or bevacizumab *Br J Ophthalmol* 97 1032-1035
- 3 Choroidal Neovascularization Prevention Trial Research Group (1998) Choroidal  
4 neovascularization in the choroidal neovascularization prevention trial *Ophthalmology* 105 (8)  
5 1364-1372
- 6 Christ SL, Lee DJ, Lam BL et al. (2008) Assessment of the effect of visual impairment on  
7 mortality through multiple health pathways: structural equation modeling *Investigative*  
8 *ophthalmology & visual science* 49 (8) 3318-3323
- 9 Christen WG, Glynn RJ, Ajani UA et al. (2001) Age-related maculopathy in a randomized trial  
10 of low-dose aspirin among US physicians *Archives of ophthalmology* (Chicago, Ill.: 1960)  
11 1143-1149
- 12 Christen WG, Glynn RJ, Chew EY et al. (2009) Low-dose aspirin and medical record-  
13 confirmed age-related macular degeneration in a randomized trial of women *Ophthalmology*  
14 2386-2392
- 15 Claxton L, Hodgson R, Taylor M et al. (2016) Simulation Modelling in Ophthalmology:  
16 Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet  
17 Age-Related Macular Degeneration in the United Kingdom *PharmacoEconomics* 1-12
- 18 Cohen SY, Creuzot-Garcher C, Darmon J et al. (2007) Types of choroidal neovascularisation  
19 in newly diagnosed exudative age-related macular degeneration *The British journal of*  
20 *ophthalmology* 91 (9) 1173-1176
- 21 Colquitt JL, Jones J, Tan SC et al. (2008) Ranibizumab and pegaptanib for the treatment of  
22 age-related macular degeneration: a systematic review and economic evaluation *Health*  
23 *Technology Assessment* 12 (16) 1-222
- 24 Complications of Age-Related Macular Degeneration Prevention Trial, 20080911 (2008) Risk  
25 factors for choroidal neovascularization and geographic atrophy in the complications of age-  
26 related macular degeneration prevention trial *Ophthalmology* 1474-1479
- 27 Complications of Age-Related Macular Degeneration Prevention Trial Research Group  
28 (2006) Laser treatment in patients with bilateral large drusen: the complications of age-  
29 related macular degeneration prevention trial *Ophthalmology* 113 (11) 1974-1986
- 30 Coscas G, Yamashiro K, Coscas F et al. (2014) Comparison of exudative age-related  
31 macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with  
32 multimodal imaging *American Journal of Ophthalmology* 158 (2) 309-318
- 33 Coscas GJ, Lupidi M, Coscas F et al. (2015) Optical coherence tomography angiography  
34 versus traditional multimodal imaging in assessing the activity of exudative age-related  
35 macular degeneration: A New Diagnostic Challenge *Retina* 35 (11) 2219-2228
- 36 Crossland MD, Helman CG, Feely MP et al. (2007) Why did i lose vision? A qualitative study  
37 of patient perceptions of the causes of age-related macular disease *Visual Impairment*  
38 *Research* 9 (1) 39-43
- 39 Curtis, L. and Burns, A. (2016) Unit costs of health and social care 2016. Personal Social  
40 Services Research Unit, University of Kent.:
- 41 Czoski Murray C, Carlton J, Brazier J et al. (2009) Valuing Condition-Specific Health States  
42 Using Simulation *Contact Lenses Value in Health* 12 (5) 793-799
- 43 Dahlin I, S, Sjostrand J et al. (1996) Planning a health education programme for the elderly  
44 visually impaired person - A focus group study *Disability and Rehabilitation* 18 (10) 515-522

- 1 Dakin HA, Wordsworth S, Rogers CA et al. (2014) Cost-effectiveness of ranibizumab and  
2 bevacizumab for age-related macular degeneration: 2-year findings from the IVAN  
3 randomised trial *BMJ Open* 4 (7) e005094-
- 4 Danis RP, Domalpally A, Chew EY et al. (2013) Methods and reproducibility of grading  
5 optimized digital color fundus photographs in the Age-Related Eye Disease Study 2  
6 (AREDS2 Report Number 2) *Investigative ophthalmology & visual science* 54 (7) 4548-4554
- 7 Datskeris I, Kontadakis GA, Diamanti R et al. (2015) Prospective comparison of low-fluence  
8 photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab  
9 monotherapy for choroidal neovascularization in age-related macular degeneration *Seminars*  
10 *in Ophthalmology* 30 112-117
- 11 Davis MD, Gangnon RE, Lee LY et al. (2005) The Age-Related Eye Disease Study severity  
12 scale for age-related macular degeneration: AREDS Report No. 17 *Archives of*  
13 *ophthalmology* (Chicago, Ill.: 1960) 123 (11) 1484-1498
- 14 Davis S, Stevenson M, Tappenden P et al. (2014) NICE DSU Technical Support Document  
15 15: Cost-Effectiveness Modelling Using Patient-Level Simulation School of Health and  
16 Related Research, University of Sheffield
- 17 de Carlo T, Bonini Filho MA, Chin AT et al. (2015) Spectral Domain Optical Coherence  
18 Tomography Angiography (OCTA) of Choroidal Neovascularization *Investigative*  
19 *ophthalmology & visual science* 56 (7) 3962-3962
- 20 De Salvo G, Vaz-Pereira S, Keane PA et al. (2014) Sensitivity and specificity of spectral-  
21 domain optical coherence tomography in detecting idiopathic polypoidal choroidal  
22 vasculopathy *American Journal of Ophthalmology* 158 (6) 1228-1238
- 23 Department of Health (2015) NHS reference costs 2014 to 2015
- 24 Department of Health (2016) Drugs and pharmaceutical electronic market information (eMit)
- 25 Do DV, Gower EW, Cassard SD et al. (2012) Detection of new-onset choroidal  
26 neovascularization using optical coherence tomography: the AMD DOC Study  
27 *Ophthalmology* 119 (4) 771-778
- 28 Dobbelsteyn D, McKee K, Bearn RD et al. (2015) What percentage of patients presenting  
29 for routine eye examinations require referral for secondary care? A study of referrals from  
30 optometrists to ophthalmologists *Clinical & Experimental Optometry* 98 (3) 214-217
- 31 Droege KM, Muether PS, Hermann MM et al. (2013) Adherence to ranibizumab treatment for  
32 neovascular age-related macular degeneration in real life *Graefes Archive for Clinical &*  
33 *Experimental Ophthalmology* 251 1281-1284
- 34 Eadie JA, Gottlieb JL, Ip MS et al. (2014) Response to aflibercept in patients with persistent  
35 exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular  
36 degeneration *Ophthalmic Surg Lasers Imaging Retina* 45 394-397
- 37 Ehliken C, Jungmann S, Bohringer D et al. (2014) Switch of anti-VEGF agents is an option for  
38 nonresponders in the treatment of AMD *Eye* 28 538-545
- 39 Eklund K, Sonn U, Dahlin-Ivanoff S (2004) Long-term evaluation of a health education  
40 programme for elderly persons with visual impairment. A randomized study *Disability &*  
41 *Rehabilitation* 26 (7) 401-409
- 42 Eklund K, Sjostrand J, Dahlin-Ivanoff S (2008) A randomized controlled trial of a health-  
43 promotion programme and its effect on ADL dependence and self-reported health problems  
44 for the elderly visually impaired *Scandinavian Journal of Occupational Therapy* 15 (2) 68-74

- 1 El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2013) Intravitreal bevacizumab in the  
2 management of neovascular age-related macular degeneration: effect of baseline visual  
3 acuity *Retina* 33 (9) 1828-1835
- 4 El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2012) Fixed-interval versus OCT-guided  
5 variable dosing of intravitreal bevacizumab in the management of neovascular age-related  
6 macular degeneration: a 12-month randomized prospective study *American Journal of*  
7 *Ophthalmology* 153 (3) 481-489
- 8 Eldem BM, Muftuoglu G, Topbas S et al. (2015) A randomized trial to compare the safety  
9 and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with  
10 choroidal neovascularization secondary to AMD *Acta Ophthalmologica* 93 (6) e458-e464
- 11 Elliot DB, Yang KC, Whitaker D (1995) Visual acuity changes throughout adulthood in  
12 normal, healthy eyes: seeing beyond 6/6 *Optometry & Vision Science* 72 (3) 186-191
- 13 Elshout M, van der Reis MI, Webers CA et al. (2012) A new epidemiological aid in deciding  
14 whether to continue or stop a treatment *Invest Ophthalmol Vis Sci* 53 4331-4336
- 15 Elshout M, van der Reis MI, Webers CA et al. (2014) The cost-utility of aflibercept for the  
16 treatment of age-related macular degeneration compared to bevacizumab and ranibizumab  
17 and the influence of model parameters *Graefe's archive for clinical and experimental*  
18 *ophthalmology* 252 (12) 1911-1920
- 19 Engman SJ, Edwards AO, Bakri SJ (2011) Administration of repeat intravitreal anti-VEGF  
20 drugs by retina specialists in an injection-only clinic for patients with exudative AMD: patient  
21 acceptance and safety *Seminars in Ophthalmology* 26 (6) 380-386
- 22 Eter N, Spaide RF (2005) Comparison of fluorescein angiography and optical coherence  
23 tomography for patients with choroidal neovascularization after photodynamic therapy *Retina*  
24 25 (6) 691-696
- 25 Evans JR, Lawrenson JG (2012) Antioxidant vitamin and mineral supplements for slowing  
26 the progression of age-related macular degeneration *The Cochrane Library*
- 27 Fang K, Tian J, Qing X et al. (2013) Predictors of visual response to intravitreal bevacizumab  
28 for treatment of neovascular age-related macular degeneration *Journal of ophthalmology*  
29 2013 676049-
- 30 Fassnacht-Riederle H, Becker M, Graf N et al. (2014) Effect of aflibercept in insufficient  
31 responders to prior anti-VEGF therapy in neovascular AMD *Graefes Arch Clin Exp*  
32 *Ophthalmol* 252 1705-1709
- 33 Figueroa MS, Regueras A, Bertrand J (1994) Laser photocoagulation to treat macular soft  
34 drusen in age-related macular degeneration *Retina* 14 (5) 391-396
- 35 Finger RP, Wu Z, Luu CD et al. (2014) Reticular pseudodrusen: a risk factor for geographic  
36 atrophy in fellow eyes of individuals with unilateral choroidal neovascularization  
37 *Ophthalmology* 1252-1256
- 38 Fleiss JL (1971) Measuring nominal scale agreement among many raters *Psychological*  
39 *bulletin* 76 (5) 378-
- 40 Fletcher EC, Lade RJ, Adewoyin T et al. (2008) Computerized model of cost-utility analysis  
41 for treatment of age-related macular degeneration *Ophthalmology* 115 (12) 2192-2198
- 42 Frennesson CI, Bek T, Jaakkola A et al. (2009) Prophylactic laser treatment of soft drusen  
43 maculopathy: a prospective, randomized Nordic study *Acta ophthalmologica* 87 (7) 720-724

- 1 Frennesson IC, Nilsson SE (1995) Effects of argon (green) laser treatment of soft drusen in  
2 early age-related maculopathy: a 6 month prospective study British Journal of  
3 Ophthalmology 79 (10) 905-909
- 4 Friberg TR, Musch DC, Lim JI et al. (2006) Prophylactic treatment of age-related macular  
5 degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible  
6 patients Ophthalmology 113 (4) 612-622
- 7 Friberg TR, Brennen PM, Freeman WR (2009) Prophylactic treatment of age-related macular  
8 degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible  
9 patients Ophthalmic Surgery, Lasers & Imaging Retina 40 (6) 530-
- 10 Friedman SM, Margo CE (2000) Choroidal neovascular membranes: reproducibility of  
11 angiographic interpretation American Journal of Ophthalmology 130 (6) 839-841
- 12 Frisen L, Frisen M (1981) How good is normal visual acuity? Graefes archive for clinical and  
13 experimental ophthalmology 215 (3) 149-157
- 14 Gehlbach P, Li T, Hatef E (2015) Statins for age-related macular degeneration The  
15 Cochrane Library
- 16 Gerding H (2015) Functional and anatomic efficacy of a conversion to aflibercept in eyes with  
17 age-related macular degeneration after long-term ranibizumab treatment Klinische  
18 Monatsblatter fur Augenheilkunde 232 (4) 560-563
- 19 Gharbiya M, Iannetti L, Parisi F et al. (2014) Visual and anatomical outcomes of intravitreal  
20 aflibercept for treatment-resistant neovascular age-related macular degeneration Biomed  
21 Res Int 2014 273754-
- 22 Ghazala F, Hovan M, Mahmood S (2013) Improving treatment provision of Wet AMD with  
23 intravitreal ranibizumab BMJ Quality Improvement Reports 2 (1)
- 24 Ghosh W, Wickstead R, Claxton L et al. (2016) The Cost-Effectiveness of Ranibizumab Treat  
25 and Extend Regimen Versus Aflibercept in the UK Advances in therapy 33 (9) 1660-1676
- 26 Giani A, Luiselli C, Esmaili DD et al. (2011) Spectral-domain optical coherence tomography  
27 as an indicator of fluorescein angiography leakage from choroidal neovascularization  
28 Investigative ophthalmology & visual science 52 (8) 5579-5586
- 29 Gillespie BW, Musch DC, Niziol LM et al. (2014) Estimating Minimally Important Differences  
30 for Two Vision-Specific Quality of Life Measures Minimally Important Difference for NEI-VFQ  
31 and VAQ Investigative ophthalmology & visual science 55 (7) 4206-4212
- 32 Gillies MC, Campain A, Barthelmes D et al. (2015) Long-Term Outcomes of Treatment of  
33 Neovascular Age-Related Macular Degeneration: Data from an Observational Study  
34 Ophthalmology 122 (9) 1837-1845
- 35 Gomi F, Oshima Y, Mori R et al. (2015) Initial Versus Delayed Photodynamic Therapy in  
36 Combination with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy Retina  
37 (Philadelphia, Pa.) 35 1569-1576
- 38 Gong J, Yu S, Gong Y et al. (2016) The Diagnostic Accuracy of Optical Coherence  
39 Tomography Angiography for Neovascular Age-Related Macular Degeneration: A  
40 Comparison with Fundus Fluorescein Angiography Journal of ophthalmology 2016 7521478-
- 41 Goudie C, Lunt D, Reid S et al. (2014) Ophthalmic digital image transfer: benefits to triage,  
42 patient care and resource Ophthalmic & Physiological Optics 34 (6) 628-635
- 43 Grieve R, Guerriero C, Walker J et al. (2009) Verteporfin photodynamic therapy cohort study:  
44 Report 3: Cost effectiveness and lessons for future evaluations Ophthalmology 116 (12)  
45 2471-2477



- 1 Griffin DR, Richmond PP, Olson JC (2014) Intravitreal Aflibercept Outcomes in Patients with  
2 Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for  
3 Neovascular Age-Related Macular Degeneration *J Ophthalmol* 2014 497178-
- 4 Grunwald JE, Daniel E, Huang J et al. (2014) Risk of geographic atrophy in the comparison  
5 of age-related macular degeneration treatments trials *Ophthalmology* 150-161
- 6 Guymer RH, Baird PN, Varsamidis M et al. (2013) Proof of concept, randomized, placebo-  
7 controlled study of the effect of simvastatin on the course of age-related macular  
8 degeneration *PLoS One* 8 (12) e83759-
- 9 Hageman GS, Gehrs K, Johnson LV et al. (2008) Age-related macular degeneration (AMD)
- 10 Hahn P, Acquah K, Cousins SW et al. (2013) Ten-year incidence of age-related macular  
11 degeneration according to diabetic retinopathy classification among medicare beneficiaries  
12 *Retina (Philadelphia, Pa.)* 911-919
- 13 Hamada S, Jain S, Sivagnanavel V et al. (2006) Drusen classification in bilateral drusen and  
14 fellow eye of exudative age-related macular degeneration *Eye (London, England)* 20 (2) 199-  
15 202
- 16 Hatz K, Schneider U, Henrich PB et al. (2015) Ranibizumab plus verteporfin photodynamic  
17 therapy in neovascular age-related macular degeneration: 12 months of retreatment and  
18 vision outcomes from a randomized study *Ophthalmologica* 233 66-73
- 19 Heier JS, Boyer D, Nguyen QD et al. (2011) The 1-year results of CLEAR-IT 2, a phase 2  
20 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed  
21 dosing *Ophthalmology* 118 (6) 1098-1106
- 22 Heier JS, Brown DM, Chong V et al. (2012) Intravitreal aflibercept (VEGF trap-eye) in wet  
23 age-related macular degeneration *Ophthalmology* 119 (12) 2537-2548
- 24 Henschel A, Spital G, Lommatzsch A et al. (2009) Optical coherence tomography in  
25 neovascular age related macular degeneration compared to fluorescein angiography and  
26 visual acuity *European Journal of Ophthalmology* 19 (5) 831-835
- 27 Hernandez-Pastor LJ, Ortega A, Garcia-Layana A et al. (2008) Cost-effectiveness of  
28 ranibizumab compared with photodynamic treatment of neovascular age-related macular  
29 degeneration *Clinical therapeutics* 30 (12) 2436-2451
- 30 Hessellund A, Larsen DA, Bek T (2012) The predictive value of subjective symptoms and  
31 clinical signs for the presence of treatment-requiring exudative age-related macular  
32 degeneration *Acta ophthalmologica* 90 (5) 471-475
- 33 Heussen FM, Shao Q, Ouyang Y et al. (2014) Clinical outcomes after switching treatment  
34 from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration  
35 *Graefes Arch Clin Exp Ophthalmol* 252 909-915
- 36 Higgins JP, Green S (2011) *Cochrane handbook for systematic reviews of interventions*. 4  
37 edition. John Wiley & Sons.
- 38 Hirneiss C (2014) The impact of a better-seeing eye and a worse-seeing eye on vision-  
39 related quality of life *Clinical ophthalmology (Auckland, NZ)* 8 1703-
- 40 Holz FG, Jorzik J, Schutt F et al. (2003) Agreement among ophthalmologists in evaluating  
41 fluorescein angiograms in patients with neovascular age-related macular degeneration for  
42 photodynamic therapy eligibility (FLAP-study) *Ophthalmology* 110 (2) 400-405
- 43 Homer N, Grewal DS, Mirza RG et al. (2015) Transitioning to intravitreal aflibercept following  
44 a previous treat-and-extend dosing regimen in neovascular age-related macular  
45 degeneration: 24-month results *Eye* 29 1152-1155

- 1 Hopley C, Salkeld G, Mitchell P (2004) Cost utility of photodynamic therapy for predominantly  
2 classic neovascular age related macular degeneration *British Journal of Ophthalmology* 88  
3 (8) 982-987
- 4 Howard KP, Klein Barbara EK, Lee KE et al. (2014) Measures of body shape and adiposity  
5 as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye  
6 Study *Investigative ophthalmology & visual science* *Invest Ophthalmol Vis Sci* 2592-  
7 2598
- 8 Huang YM, Dou HL, Huang FF et al. (2015) Changes following supplementation with lutein  
9 and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a  
10 randomised, double-blind, placebo-controlled trial *British Journal of Ophthalmology* 99 (3)  
11 371-375
- 12 Hurley SF, Matthews JP, Guymer RH (2008) Cost-effectiveness of ranibizumab for  
13 neovascular age-related macular degeneration *Cost Effectiveness and Resource Allocation* 6  
14 (1) 1-
- 15 Jaeschke R, Guyatt GH, Sackett DL et al. (1994) Users' Guides to the Medical Literature: III.  
16 How to Use an Article About a Diagnostic Test B. What Are the Results and Will They Help  
17 Me in Caring for My Patients? *JAMA* 271 (9) 703-707
- 18 JOINT FORMULARY COMMITTEE (2016) *British National Formulary*. BMJ Group and  
19 Pharmaceutical Press.
- 20 Jung JJ, Chen CY, Mrejen S et al. (2014) The incidence of neovascular subtypes in newly  
21 diagnosed neovascular age-related macular degeneration *American Journal of*  
22 *Ophthalmology* 158 (4) 769-779
- 23 Kaiser PK, Boyer DS, Cruess AF et al. (2012) Verteporfin plus ranibizumab for choroidal  
24 neovascularization in age-related macular degeneration: twelve-month results of the DENALI  
25 study *Ophthalmology* 119 1001-1010
- 26 Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy  
27 (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in  
28 age-related macular degeneration: 5-year results of two randomized clinical trials with an  
29 open-label extension *Graefes archive for clinical and experimental ophthalmology* 244 (9)  
30 1132-1142
- 31 Kaiser PK (2009) Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a  
32 randomized trial *Current medical research and opinion* 25 (8) 1853-1860
- 33 Kaiser RS, Gupta OP, Regillo CD et al. (2012) Ranibizumab for eyes previously treated with  
34 pegaptanib or bevacizumab without clinical response *Ophthalmic Surg Lasers Imaging* 43  
35 13-19
- 36 Kaltenthaler E, Tappenden P, Paisley S et al. (2011) NICE DSU technical support document  
37 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-  
38 effectiveness models *Sheffield: Decision Support Unit, SchARR, University of Sheffield*
- 39 Kamalarajah S, Silvestri G, Sharma N et al. (2004) Surveillance of endophthalmitis following  
40 cataract surgery in the UK *Eye* 18 (6) 580-587
- 41 Kawashima Y, Oishi A, Tsujikawa A et al. (2015) Effects of aflibercept for ranibizumab-  
42 resistant neovascular age-related macular degeneration and polypoidal choroidal  
43 vasculopathy *Graefes Arch Clin Exp Ophthalmol* 253 1471-1477
- 44 Khurana RN, Dupas B, Bressler NM (2010) Agreement of time-domain and spectral-domain  
45 optical coherence tomography with fluorescein leakage from choroidal neovascularization  
46 *Ophthalmology* 117 (7) 1376-1380

- 1 Kind P, Hardman G, Macran S (1999) UK population norms for EQ-5D. 172 edition. Centre  
2 for Health Economics, University of York York.
- 3 Klein Barbara EK, Howard KP, Gangnon RE et al. (2012) Long-term use of aspirin and age-  
4 related macular degeneration JAMA 2469-2478
- 5 Klein ML, Francis PJ, Ferris FL, III et al. (2011) Risk assessment model for development of  
6 advanced age-related macular degeneration Archives of ophthalmology (Chicago, Ill.: 1960)  
7 129 (12) 1543-1550
- 8 Klein ML, Francis PJ, Ferris FL et al. (2011) Risk assessment model for development of  
9 advanced age-related macular degeneration Archives of ophthalmologyArch Ophthalmol  
10 1543-1550
- 11 Klein R, Klein BE, Knudtson MD et al. (2007) Fifteen-year cumulative incidence of age-  
12 related macular degeneration: the Beaver Dam Eye Study Ophthalmology 253-262
- 13 Klein R, Meuer SM, Knudtson MD et al. (2008) The epidemiology of retinal reticular drusen  
14 American journal of ophthalmologyAm J Ophthalmol 317-326
- 15 Klein R, Meuer SM, Myers CE et al. (2014) Harmonizing the classification of age-related  
16 macular degeneration in the three-continent AMD consortium Ophthalmic epidemiology 21  
17 (1) 14-23
- 18 Klein R, Knudtson MD, Cruickshanks KJ et al. (2008) Further observations on the  
19 association between smoking and the long-term incidence and progression of age-related  
20 macular degeneration: the Beaver Dam Eye Study Archives of ophthalmology (Chicago, Ill.:  
21 1960) 115-121
- 22 Klein R, Cruickshanks KJ, Myers CE et al. (2013) The relationship of atherosclerosis to the  
23 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies  
24 Ophthalmology 1012-1019
- 25 Knudtson MD, Klein R, Klein BE (2006) Physical activity and the 15-year cumulative  
26 incidence of age-related macular degeneration: the Beaver Dam Eye Study British Journal of  
27 OphthalmologyBr.J.Ophthalmol. 1461-1463
- 28 Kodjikian L, Souied EH, Mimoun G et al. (2013) Ranibizumab versus bevacizumab for  
29 neovascular age-related macular degeneration: results from the GEFAL noninferiority  
30 randomized trial Ophthalmology 120 (11) 2300-2309
- 31 Koh A, Lee WK, Chen LJ et al. (2012) EVEREST study: efficacy and safety of verteporfin  
32 photodynamic therapy in combination with ranibizumab or alone versus ranibizumab  
33 monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina  
34 32 1453-1464
- 35 Krebs I, Vecsei M, V et al. (2013) Comparison of Ranibizumab monotherapy versus  
36 combination of Ranibizumab with photodynamic therapy with neovascular age-related  
37 macular degeneration Acta Ophthalmologica 91 e178-e183
- 38 Krebs I, Schmetterer L, Boltz A et al. (2013) A randomised double-masked trial comparing  
39 the visual outcome after treatment with ranibizumab or bevacizumab in patients with  
40 neovascular age-related macular degeneration British Journal of Ophthalmology 97 (3) 266-  
41 271
- 42 Kucukerdonmez C, Gelisken F, Yoeruek E et al. (2015) Switching intravitreal anti-VEGF  
43 treatment in neovascular age-related macular degeneration Eur J Ophthalmol 25 51-56
- 44 Kumar N, Marsiglia M, Mrejen S et al. (2013) Visual and anatomical outcomes of intravitreal  
45 aflibercept in eyes with persistent subfoveal fluid despite previous treatments with

- 1 ranibizumab in patients with neovascular age-related macular degeneration *Retina* 33 1605-  
2 1612
- 3 Kuppermann BD, Goldstein M, Maturi RK et al. (2015) Dexamethasone Intravitreal Implant  
4 as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A  
5 Multicenter Randomized Controlled Trial *Ophthalmologica* 234 40-54
- 6 Larsen M, Schmidt-Erfurth U, Lanzetta P et al. (2012) Verteporfin plus ranibizumab for  
7 choroidal neovascularization in age-related macular degeneration: twelve-month MONT  
8 BLANC study results *Ophthalmology* 119 992-1000
- 9 Lawrenson JG, Evans JR (2015) Omega 3 fatty acids for preventing or slowing the  
10 progression of age-related macular degeneration *The Cochrane Library*
- 11 Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and  
12 alone in choroidal neovascularization due to age-related macular degeneration  
13 *Ophthalmology* 114 1179-1185
- 14 Lechanteur Yara TE, van d, V, Johannes PH et al. (2012) Genetic, behavioral, and  
15 sociodemographic risk factors for second eye progression in age-related macular  
16 degeneration *Investigative ophthalmology & visual science* *Invest Ophthalmol Vis Sci*  
17 5846-5852
- 18 Li B, Powell AM, Hooper PL et al. (2015) Prospective evaluation of teleophthalmology in  
19 screening and recurrence monitoring of neovascular age-related macular degeneration: a  
20 randomized clinical trial *JAMA Ophthalmology* 133 (3) 276-282
- 21 Li X, Hu Y, Sun X et al. (2012) Bevacizumab for neovascular age-related macular  
22 degeneration in China *Ophthalmology* 119 (10) 2087-2093
- 23 Lim JH, Wickremasinghe SS, Xie J et al. (2012) Delay to treatment and visual outcomes in  
24 patients treated with anti-vascular endothelial growth factor for age-related macular  
25 degeneration *American Journal of Ophthalmology* 153 (4) 678-86, 686
- 26 Lim JY, Lee SY, Kim JG et al. (2012) Intravitreal bevacizumab alone versus in combination  
27 with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50  
28 years or older: 1-year results of a prospective clinical study *Acta Ophthalmologica* 90 61-67
- 29 Lim JI, Labree L, Nichols T et al. (2002) Comparison of nonmydriatic digitized video fundus  
30 images with standard 35-mm slides to screen for and identify specific lesions of age-related  
31 macular degeneration *Retina* 22 (1) 59-64
- 32 Little HL, Showman JM, Brown BW (1997) A pilot randomized controlled study on the effect  
33 of laser photocoagulation of confluent soft macular drusen *Ophthalmology* 104 (4) 623-631
- 34 Lushchik T, Amarakoon S, Martinez-Ciriano J et al. (2013) Bevacizumab in age-related  
35 macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks,  
36 6 weeks and 8 weeks *Acta ophthalmologica* 91 (6) e456-e461
- 37 Maberley DAL, Isbister C, Mackenzie P et al. (2005) An evaluation of photographic screening  
38 for neovascular age-related macular degeneration *Eye* 19 (6) 611-616
- 39 Macaskill P, Gatsonis C, Deeks J et al. (2010) *Cochrane handbook for systematic reviews of*  
40 *diagnostic test accuracy* Version 0.9.0. London: The Cochrane Collaboration
- 41 Maguire MG, Alexander J, Fine SL (2008) Characteristics of choroidal neovascularization in  
42 the complications of age-related macular degeneration prevention trial *Ophthalmology* 115  
43 (9) 1468-73, 1473
- 44 Maguire MG, Bressler SB, Bressler NM et al. (1997) Risk factors for choroidal  
45 neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal

- 1 neovascularization secondary to age-related macular degeneration Archives of  
2 Ophthalmology 115 (6) 741-747
- 3 Maguire MG, Ying GS, McCannel CA et al. (2009) Statin use and the incidence of advanced  
4 age-related macular degeneration in the Complications of Age-related Macular Degeneration  
5 Prevention Trial Ophthalmology 116 (12) 2381-2385
- 6 Mahmood S, Roberts SA, Aslam TM et al. (2015) Routine versus as-needed bevacizumab  
7 with 12-weekly assessment intervals for neovascular age-related macular degeneration: 92-  
8 week results of the gman trial Ophthalmology 122 (7) 1348-1355
- 9 Mantel I, Gianniou C, Dirani A (2016) Conversion to Aflibercept Therapy Versus Continuing  
10 with Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration Dependent  
11 on Monthly Ranibizumab Treatment Retina 36 53-58
- 12 Markun S, Dishy A, Neuner-Jehle S et al. (2015) The Chronic Care for Wet Age Related  
13 Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial PLoS ONE  
14 [Electronic Resource] 10 (11) e0143085-
- 15 Martin DF, Maguire MG, Fine SL et al. (2012) Ranibizumab and bevacizumab for treatment  
16 of neovascular age-related macular degeneration: two-year results Ophthalmology 119 (7)  
17 1388-1398
- 18 Mathew R, Pefkianaki M, Kopsachilis N et al. (2013) Correlation of fundus fluorescein  
19 angiography and spectral-domain optical coherence tomography in identification of  
20 membrane subtypes in neovascular age-related macular degeneration Ophthalmologica 231  
21 (3) 153-159
- 22 McCloud C, Khadka J, Gilhotra JS et al. (2014) Divergence in the lived experience of people  
23 with macular degeneration Optometry & Vision Science 91 966-974
- 24 McCloud C, Lake S (2015) Understanding the patient's lived experience of neovascular age-  
25 related macular degeneration: a qualitative study Eye 29 (12) 1561-1569
- 26 McCrone PR, Dhanasiri S, Patel A, et al. (2008) Paying the price: the cost of mental health  
27 care in England to 2026. King's Fund.
- 28 McKibbin M, Devonport H, Gale R et al. (2015) Aflibercept in wet AMD beyond the first year  
29 of treatment: recommendations by an expert roundtable panel Eye (London, England)  
30 2015/07/15 S1-s11
- 31 Meads C, Moore D (2001) The clinical effectiveness and cost utility of photodynamic therapy  
32 for age-related macular degeneration: REP Committee draft report with amendments  
33 Birmingham: Regional Evaluation Panel (REP)
- 34 Meads C, Hyde C (2003) What is the cost of blindness? British Journal of Ophthalmology 87  
35 (10) 1201-1204
- 36 Meads C, Salas C, Roberts T et al. (2003) Clinical effectiveness and cost-utility of  
37 photodynamic therapy for wet age-related macular degeneration: a systematic review and  
38 economic evaluation
- 39 Menon G, Chandran M, Sivaprasad S et al. (2013) Is it necessary to use three mandatory  
40 loading doses when commencing therapy for neovascular age-related macular degeneration  
41 using bevacizumab? (BeMOc Trial) Eye 27 (8) 959-963
- 42 Messori A (2017) Controversies in Using Off-Label Intravitreal Bevacizumab for Patients  
43 With Diabetic Macular Edema JAMA Ophthalmology

- 1 Mitchell J, Bradley P, Anderson SJ et al. (2002) Perceived quality of health care in macular  
2 disease: a survey of members of the Macular Disease Society British Journal of  
3 Ophthalmology 86 777-781
- 4 Mitchell P, Korobelnik JF, Lanzetta P et al. (2010) Ranibizumab (Lucentis) in neovascular  
5 age-related macular degeneration: evidence from clinical trials The British journal of  
6 ophthalmology 2009/05/16 2-13
- 7 Moisseiev E, Katz G, Moisseiev J et al. (2015) SWITCHING TREATMENT FOR  
8 NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO  
9 RANIBIZUMAB: Who is Likely to Benefit From the Switch? Retina 35 1323-1330
- 10 Mokwa NF, Ristau T, Keane PA et al. (2013) Grading of age-related macular degeneration:  
11 comparison between color fundus photography, fluorescein angiography, and spectral  
12 domain optical coherence tomography Journal of ophthalmology 2013
- 13 Mowatt G, Hernández R, Castillo M et al. (2014) Optical coherence tomography for the  
14 diagnosis, monitoring and guiding of treatment for neovascular age-related macular  
15 degeneration: a systematic review and economic evaluation Health Technology Assessment
- 16 Muen WJ, Hewick SA (2011) Quality of optometry referrals to neovascular age-related  
17 macular degeneration clinic: a prospective study JRSM Short Reports 2 (8) 64-
- 18 Muether PS, Hermann MM, Koch K et al. (2011) Delay between medical indication to anti-  
19 VEGF treatment in age-related macular degeneration can result in a loss of visual acuity  
20 Graefes Archive for Clinical & Experimental Ophthalmology 249 (5) 633-637
- 21 Muether PS, Hoerster R, Hermann MM et al. (2013) Long-term effects of ranibizumab  
22 treatment delay in neovascular age-related macular degeneration Graefes Archive for  
23 Clinical & Experimental Ophthalmology 251 (2) 453-458
- 24 Murray IJ, Makridaki M, van der Veen RL et al. (2013) Lutein Supplementation over a One-  
25 Year Period in Early AMD Might Have a Mild Beneficial Effect on Visual Acuity: The CLEAR  
26 Study Effect of Lutein Supplementation on Visual Acuity Investigative ophthalmology & visual  
27 science 54 (3) 1781-1788
- 28 Narayan DS, Muecke J (2015) Intravitreal aflibercept treatment in eyes with exudative age-  
29 related macular degeneration following prior treatment with intravitreal ranibizumab Indian J  
30 Ophthalmol 63 832-836
- 31 National Institute for Clinical Excellence (2003) Guidance on the use of photodynamic  
32 therapy for age-related macular degeneration. NICE technology appraisal guidance (TA68)
- 33 National Institute for Health and Care Excellence (2013) Aflibercept solution for injection for  
34 treating wet age-related macular degeneration. NICE technology appraisal guidance (TA294)
- 35 National Institute for Health and Care Excellence (2014) Developing NICE guidelines: the  
36 manual
- 37 National Institute for Health and Care Excellence (2015) Aflibercept for treating diabetic  
38 macular oedema. NICE technology appraisal guidance (TA346)
- 39 National Institute for Health and Care Excellence (2016) Cardiovascular disease: risk  
40 assessment and reduction, including lipid modification. NICE guideline (CG181)
- 41 National Institute for Health and Clinical Excellence (2008) Ranibizumab and pegaptanib for  
42 the treatment of age-related macular degeneration. NICE technology appraisal guidance  
43 (TA155)
- 44 National Institute for Health and Clinical Excellence (2011) Ranibizumab for the treatment of  
45 diabetic macular oedema. NICE technology appraisal guidance (TA237)

- 1 Neubauer AS, Holz FG, Sauer S et al. (2010) Cost-effectiveness of ranibizumab for the  
2 treatment of neovascular age-related macular degeneration in Germany: Model analysis from  
3 the perspective of Germany's statutory health insurance system *Clinical therapeutics* 32 (7)  
4 1343-1356
- 5 Newsome DA, Swartz M, Leone NC et al. (1988) Oral zinc in macular degeneration *Archives*  
6 *of Ophthalmology* 106 (2) 192-198
- 7 NHS Business Services Authority, NHS Prescription Services (2017) National Health Service  
8 Drug Tariff for England and Wales
- 9 NHS Digital (2015) Hospital outpatient activity - 2014-15: main procedure of intervention
- 10 NHS Digital (2015) Hospital episode statistics, admitted patient care - England, 2014-15:  
11 procedures and interventions
- 12 Nomura Y, Yanagi Y (2015) Intravitreal aflibercept for ranibizumab-resistant exudative age-  
13 related macular degeneration with choroidal vascular hyperpermeability *Jpn J Ophthalmol* 59  
14 261-265
- 15 Nunes RP, Nobrega MJ, De N et al. (2010) Causes of interruption of bevacizumab therapy in  
16 age-related macular degeneration *Arquivos Brasileiros de Oftalmologia* 73 146-149
- 17 Office for National Statistics (2017) National life tables, UK: 2013-2015
- 18 Oishi A, Kojima H, Mandai M et al. (2013) Comparison of the effect of ranibizumab and  
19 verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results *American*  
20 *Journal of Ophthalmology* 156 (4) 644-651
- 21 Oliver-Fernandez A, Bakal J, Segal S et al. (2005) Progression of visual loss and time  
22 between initial assessment and treatment of wet age-related macular degeneration *Canadian*  
23 *Journal of Ophthalmology* 40 (3) 313-319
- 24 Olk RJ, Friberg TR, Stickney KL et al. (1999) Therapeutic benefits of infrared (810-nm) diode  
25 laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related  
26 macular degeneration: two-year results of a randomized pilot study *Ophthalmology* 106 (11)  
27 2082-2090
- 28 Olk RJ, Peralta E, Gierhart DL et al. (2015) Triple combination therapy and zeaxanthin for  
29 the treatment of neovascular age-related macular degeneration: an interventional  
30 comparative study and cost-effectiveness analysis *International Journal of Retina and*  
31 *Vitreous* 1 (1) 1-
- 32 Olsen TW, Feng X, Kasper TJ et al. (2004) Fluorescein angiographic lesion type frequency in  
33 neovascular age-related macular degeneration *Ophthalmology* 111 (2) 250-255
- 34 Owens SL, Bunce C, Brannon AJ et al. (2003) Prophylactic laser treatment appears to  
35 promote choroidal neovascularisation in high-risk ARM: results of an interim analysis *Eye* 17  
36 (5) 623-627
- 37 Padnick-Silver L, Weinberg AB, Lafranco FP et al. (2012) Pilot study for the detection of early  
38 exudative age-related macular degeneration with optical coherence tomography *Retina* 32  
39 (6) 1045-1056
- 40 Panchmatia HR, Clements KM, Hulbert E et al. (2016) Aflibercept vs. Ranibizumab:  
41 cost-effectiveness of treatment for wet age-related macular degeneration in Sweden *Acta*  
42 *ophthalmologica*
- 43 Parodi MB, Toto L, Mastropasqua L et al. (2004) Prismatic correction in patients affected by  
44 age-related macular degeneration *Clinical Rehabilitation* 18 (7) 828-832

- 1 Patel JJ, Mendes MA, Bounthavong M et al. (2012) Cost-utility analysis of bevacizumab
- 2 versus ranibizumab in neovascular age-related macular degeneration using a Markov model
- 3 *Journal of evaluation in clinical practice* 18 (2) 247-255
  
- 4 Patel KH, Chow CC, Rathod R et al. (2013) Rapid response of retinal pigment epithelial
- 5 detachments to intravitreal aflibercept in neovascular age-related macular degeneration
- 6 refractory to bevacizumab and ranibizumab *Eye* 27 663-667
  
- 7 Perlee LT, Bansal AT, Gehrs K et al. (2013) Inclusion of genotype with fundus phenotype
- 8 improves accuracy of predicting choroidal neovascularization and geographic atrophy
- 9 *Ophthalmology* 120 (9) 1880-1892
  
- 10 Piermarocchi S, Saviano S, Parisi V et al. (2012) Carotenoids in Age-related Maculopathy
- 11 Italian Study (CARMIS): two-year results of a randomized study *European Journal of*
- 12 *Ophthalmology* 22 (2) 216-
  
- 13 Pinheiro-Costa J, Costa JM, Beato JN et al. (2015) Switch to Aflibercept in the Treatment of
- 14 Neovascular AMD: One-Year Results in Clinical Practice *Ophthalmologica* 233 155-161
  
- 15 Pirbhai A, Sheidow T, Hooper P (2005) Prospective evaluation of digital non-stereo color
- 16 fundus photography as a screening tool in age-related macular degeneration *American*
- 17 *Journal of Ophthalmology* 139 (3) 455-461
  
- 18 Piri N, Ahmadieh H, Taei R et al. (2014) Photodynamic Therapy and Intravitreal
- 19 Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular
- 20 Degeneration; a Randomized Clinical Trial *Journal of Ophthalmic & Vision Research* 9 469-
- 21 477
  
- 22 Raftery J, Clegg A, Jones J et al. (2007) Ranibizumab (Lucentis) versus bevacizumab
- 23 (Avastin): modelling cost effectiveness *British Journal of Ophthalmology* 91 (9) 1244-1246
  
- 24 Ranchod TM, Ray SK, Daniels SA et al. (2013) LuceDex: a prospective study comparing
- 25 ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for
- 26 neovascular age-related macular degeneration *Retina* 33 1600-1604
  
- 27 Rasmussen A, Brandi S, Fuchs J et al. (2015) Visual outcomes in relation to time to
- 28 treatment in neovascular age-related macular degeneration *Acta Ophthalmologica* 93 (7) 616-
- 29 620
  
- 30 Rasul A, Subhi Y, Sorensen TL et al. (2016) Non-Physician delivered intravitreal injection
- 31 service is feasible and safe - A systematic review *Danish Medical Journal* 63 (5) no-
  
- 32 Rauch R, Weingessel B, Maca SM et al. (2012) Time to first treatment: The significance of
- 33 early treatment of exudative age-related macular degeneration *Retina* 32 (7) 1260-1264
  
- 34 Real JP, Luna JD, Urrets-Zavalía JA et al. (2013) Accessibility as a conditioning factor in
- 35 treatment for exudative age-related macular degeneration *European Journal of*
- 36 *Ophthalmology* 23 (6) 857-864
  
- 37 Reeves BC, Harper RA, Russell WB (2004) Enhanced low vision rehabilitation for people
- 38 with age related macular degeneration: a randomised controlled trial *British Journal of*
- 39 *Ophthalmology* 88 (11) 1443-1449
  
- 40 Reeves BC, Scott LJ, Taylor J et al. (2016) Effectiveness of Community versus Hospital Eye
- 41 Service follow-up for patients with neovascular age-related macular degeneration with
- 42 quiescent disease (ECHOES): a virtual non-inferiority trial *BMJ Open* 6 (7) e010685-
  
- 43 Regillo CD, Busbee BG, Ho AC et al. (2015) Baseline Predictors of 12-Month Treatment
- 44 Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration
- 45 *American Journal of Ophthalmology* 160 (5) 1014-1023



- 1 Regillo CD, Brown DM, Abraham P et al. (2008) Randomized, double-masked, sham-
- 2 controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study
- 3 year 1 American Journal of Ophthalmology 145 (2) 239-248
- 4 Rein DB, Saaddine JB, Wittenborn JS et al. (2007) Cost-effectiveness of vitamin therapy for
- 5 age-related macular degeneration Ophthalmology 114 (7) 1319-1326
- 6 Reynolds R, Rosner B, Seddon JM (2013) Dietary omega-3 fatty acids, other fat intake,
- 7 genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 1020-
- 8 1028
- 9 Richer S (1996) Multicenter ophthalmic and nutritional age-related macular degeneration
- 10 study--part 2: antioxidant intervention and conclusions Journal of the American Optometric
- 11 Association 67 (1) 30-49
- 12 Richer S, Stiles W, Statkute L et al. (2004) Double-masked, placebo-controlled, randomized
- 13 trial of lutein and antioxidant supplementation in the intervention of atrophic age-related
- 14 macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial)
- 15 Optometry-Journal of the American Optometric Association 75 (4) 216-229
- 16 Rofagha S, Bhisitkul RB, Boyer DS et al. (2013) Seven-year outcomes in ranibizumab-
- 17 treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-
- 18 UP) Ophthalmology 120 (11) 2292-2299
- 19 Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related
- 20 macular degeneration N Engl J Med 355 1419-1431
- 21 Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related
- 22 macular degeneration New England Journal of Medicine 355 (14) 1419-1431
- 23 Rovner BW, Casten RJ, Hegel MT et al. (2007) Preventing depression in age-related
- 24 macular degeneration Archives of General Psychiatry 64 (8) 886-892
- 25 Rovner BW, Casten RJ, Hegel MT et al. (2013) Improving function in age-related macular
- 26 degeneration: a randomized clinical trial Ophthalmology 120 (8) 1649-1655
- 27 Rovner BW, Casten RJ, Hegel MT et al. (2014) Low vision depression prevention trial in age-
- 28 related macular degeneration: a randomized clinical trial Ophthalmology 121 (11) 2204-2211
- 29 Sacu S, Michels S, Prager F et al. (2009) Randomised clinical trial of intravitreal Avastin vs
- 30 photodynamic therapy and intravitreal triamcinolone: long-term results Eye 23 (12) 2223-
- 31 2227
- 32 Saito M, Kano M, Itagaki K et al. (2014) Switching to intravitreal aflibercept injection for
- 33 polypoidal choroidal vasculopathy refractory to ranibizumab Retina 34 2192-2201
- 34 Saito M, Kano M, Itagaki K et al. (2016) Subfoveal choroidal thickness in polypoidal choroidal
- 35 vasculopathy after switching to intravitreal aflibercept injection Jpn J Ophthalmol 60 35-41
- 36 Salinas-Alaman A, Garcia-Layana A, Maldonado MJ et al. (2005) Using optical coherence
- 37 tomography to monitor photodynamic therapy in age related macular degeneration American
- 38 Journal of Ophthalmology 140 (1) 23-28
- 39 Sallet G, Lafaut BA, De Laey JJ (1996) Indocyanine green angiography and age-related
- 40 serous pigment epithelial detachment Graefe's archive for clinical and experimental
- 41 ophthalmology 234 (1) 25-33
- 42 Sandberg MA, Weiner A, Miller S et al. (1998) High-risk characteristics of fellow eyes of
- 43 patients with unilateral neovascular age-related macular degeneration Ophthalmology 441-
- 44 447

- 1 Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without  
2 additional colour fundus photography, with stereo fundus fluorescein angiography in  
3 diagnosing choroidal neovascular membranes *British Journal of Ophthalmology* 89 (8) 967-  
4 970
- 5 Sarao V, Parravano M, Veritti D et al. (2016) Intravitreal Aflibercept for Choroidal  
6 Neovascularization Due to Age-Related Macular Degeneration Unresponsive to  
7 Ranibizumab Therapy *Retina* 36 (4) 770-777
- 8 Scanlon PH, Loftus J, Starita C et al. (2015) The use of weighted health-related Quality of  
9 Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial  
10 *Diabetic Medicine* 32 (1) 97-101
- 11 Schauwvlieghe AME, Dijkman G, Hooymans JM et al. (2016) Comparing the effectiveness of  
12 bevacizumab to ranibizumab in patients with exudative age-related macular degeneration.  
13 The BRAMD study *PLoS One* 11 (5) no-
- 14 Schmidt-Erfurth U, Eldem B, Guymer R et al. (2011) Efficacy and safety of monthly versus  
15 quarterly ranibizumab treatment in neovascular age-related macular degeneration: the  
16 EXCITE study *Ophthalmology* 118 (5) 831-839
- 17 Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al. (2014) Intravitreal Aflibercept Injection for  
18 Neovascular Age-related Macular Degeneration: Ninety-Six-week Results of the VIEW Studies  
19 *Ophthalmology* 121 (1) 193-201
- 20 Schmier JK, Halpern MT, Covert D et al. (2006) Impact of visual impairment on use of  
21 caregiving by individuals with age-related macular degeneration *Retina* 26 (9) 1056-1062
- 22 Schwartz AL, Meek PM, Nail LM et al. (2002) Measurement of fatigue: determining minimally  
23 important clinical differences *Journal of clinical epidemiology* 55 (3) 239-244
- 24 Seddon JM, Sharma S, Adelman RA (2006) Evaluation of the clinical age-related  
25 maculopathy staging system *Ophthalmology* 113 (2) 260-266
- 26 Seddon JM, Cote J, Davis N et al. (2003) Progression of age-related macular degeneration:  
27 association with body mass index, waist circumference, and waist-hip ratio *Archives of*  
28 *ophthalmology (Chicago, Ill.: 1960)* 785-792
- 29 Seddon JM, Cote J, Rosner B (2003) Progression of age-related macular degeneration:  
30 association with dietary fat, transunsaturated fat, nuts, and fish intake *Archives of*  
31 *ophthalmology (Chicago, Ill.: 1960)* 1728-1737
- 32 Seddon JM, Reynolds R, Yu Y et al. (2011) Risk models for progression to advanced age-  
33 related macular degeneration using demographic, environmental, genetic, and ocular factors  
34 *Ophthalmology* 2203-2211
- 35 Seddon JM, Reynolds R, Yu Y et al. (2013) Validation of a prediction algorithm for  
36 progression to advanced macular degeneration subtypes *JAMA ophthalmology*  
37 *Ophthalmol* 448-455
- 38 Seddon JM, Silver RE, Kwong M et al. (2015) Risk Prediction for Progression of Macular  
39 Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and  
40 Macular Covariates *Investigative ophthalmology & visual science*  
41 *Invest Ophthalmol Vis Sci* 2192-2202
- 42 Semeraro F, Russo A, Delcassi L et al. (2015) Treatment of Exudative Age-Related Macular  
43 Degeneration with Ranibizumab Combined with Ketorolac Eyedrops or Photodynamic  
44 Therapy *Retina* 35 1547-1554

- 1 Shaikh AH, Toussaint BW, Miller DM et al. (2015) Cost comparison of intravitreal aflibercept  
2 with bevacizumab and ranibizumab for the treatment of wet age-related macular  
3 degeneration *Ophthalmic Surg Lasers Imaging Retina* 46 62-66
- 4 Sharma S, Brown GC, Brown MM et al. (2000) The cost-effectiveness of grid laser  
5 photocoagulation for the treatment of diabetic macular edema: results of a patient-based  
6 cost-utility analysis *Current opinion in ophthalmology* 11 (3) 175-179
- 7 Shea BJ, Grimshaw JM, Wells GA et al. (2007) Development of AMSTAR: a measurement  
8 tool to assess the methodological quality of systematic reviews *BMC medical research  
9 methodology* 7 (1) 10-
- 10 Shiragami C, Ono A, Kobayashi M et al. (2014) Effect of switching therapy to pegaptanib in  
11 eyes with the persistent cases of exudative age-related macular degeneration 93 no-
- 12 Simcock P, Kingett B, Mann N et al. (2014) A safety audit of the first 10 000 intravitreal  
13 ranibizumab injections performed by nurse practitioners *Eye (Basingstoke)* 28 (10) 1161-  
14 1164
- 15 Smith DH, Fenn P, Drummond M (2004) Cost effectiveness of photodynamic therapy with  
16 verteporfin for age related macular degeneration: the UK case *British Journal of  
17 Ophthalmology* 88 (9) 1107-1112
- 18 Smith HJ, Dickinson CM, Cacho I et al. (2005) A randomized controlled trial to determine the  
19 effectiveness of prism spectacles for patients with age-related macular degeneration  
20 *Archives of Ophthalmology* 123 (8) 1042-1050
- 21 Solomon SD, Lindsley K, Vedula SS et al. (2014) Anti-vascular endothelial growth factor for  
22 neovascular age-related macular degeneration *The Cochrane Library*
- 23 Souied EH, Delcourt C+, Querques G et al. (2013) Oral docosahexaenoic acid in the  
24 prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2  
25 study *Ophthalmology* 120 (8) 1619-1631
- 26 Stein JD, VanderBeek BL, Talwar N et al. (2011) Rates of nonexudative and exudative age-  
27 related macular degeneration among Asian American ethnic groups *Investigative  
28 ophthalmology & visual science* Invest Ophthalmol Vis Sci 6842-6848
- 29 Stein JD, Newman-Casey PA, Mrinalini T et al. (2014) Cost-effectiveness of bevacizumab  
30 and ranibizumab for newly diagnosed neovascular macular degeneration *Ophthalmology* 121  
31 (4) 936-945
- 32 Steinbrook R (2006) The price of sight—ranibizumab, bevacizumab, and the treatment of  
33 macular degeneration *New England Journal of Medicine* 355 (14) 1409-1412
- 34 Stur M, Tittl M, Reitner A et al. (1996) Oral zinc and the second eye in age-related macular  
35 degeneration *Investigative ophthalmology & visual science* 37 (7) 1225-1235
- 36 Submacular Surgery Trials Research Group, Solomon, Jefferys SD et al. (2009) Risk factors  
37 for second eye progression to advanced age-related macular degeneration: SST report No.  
38 21 Submacular Surgery Trials Research Group *Retina (Philadelphia, Pa.)* Retina 1080-1090
- 39 Submacular Surgery Trials Research Group (2009) Risk factors for second eye progression  
40 to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery  
41 Trials Research Group *Retina* 29 (8) 1080-1090
- 42 Subramanian ML, Abedi G, Ness S et al. (2010) Bevacizumab vs ranibizumab for age-  
43 related macular degeneration: 1-year outcomes of a prospective, double-masked  
44 randomised clinical trial *Eye* 24 (11) 1708-1715

- 1 Sullivan PW, Slejko JF, Sculpher MJ et al. (2011) Catalogue of EQ-5D scores for the United  
2 Kingdom Medical Decision Making 31 (6) 800-804
- 3 Sunness JS, Gonzalez-Baron J, Applegate CA et al. (1999) Enlargement of atrophy and  
4 visual acuity loss in the geographic atrophy form of age-related macular degeneration  
5 Ophthalmology 106 (9) 1768-1779
- 6 Takahashi H, Ohkubo Y, Sato A et al. (2015) Relationship between visual prognosis and  
7 delay of intravitreal injection of ranibizumab when treating age-related macular degeneration  
8 Retina 35 (7) 1331-1338
- 9 Talks J, Koshy Z, Chatzinikolas K (2007) Use of optical coherence tomography, fluorescein  
10 angiography and indocyanine green angiography in a screening clinic for wet age-related  
11 macular degeneration British Journal of Ophthalmology 91 (5) 600-601
- 12 Tao Y, Jonas JB (2010) Intravitreal bevacizumab combined with intravitreal triamcinolone for  
13 therapy-resistant exudative age-related macular degeneration J Ocul Pharmacol Ther 26  
14 207-212
- 15 Tappenden P, Chilcott J, Brennan A et al. (2012) Whole disease modeling to inform resource  
16 allocation decisions in cancer: a methodological framework Value in Health 15 (8) 1127-1136
- 17 Tappenden P, Chilcott J, Brennan A et al. (2013) Using whole disease modeling to inform  
18 resource allocation decisions: economic evaluation of a clinical guideline for colorectal  
19 cancer using a single model Value in Health 16 (4) 542-553
- 20 The Royal College of Ophthalmologists (2013) age-related macular degeneration: guidelines  
21 for management. London:
- 22 Thompson AC, Thompson MO, Young DL et al. (2015) Barriers to Follow-Up and Strategies  
23 to Improve Adherence to Appointments for Care of Chronic Eye Diseases Investigative  
24 ophthalmology & visual science 56 4324-4331
- 25 Thorell MR, Nunes RP, Chen GW et al. (2014) Response to aflibercept after frequent re-  
26 treatment with bevacizumab or ranibizumab in eyes with neovascular AMD Ophthalmic Surg  
27 Lasers Imaging Retina 45 526-533
- 28 Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group  
29 (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related  
30 macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP  
31 report 1 Archives of Ophthalmology 117 (10) 1329-
- 32 Tschuor P, Pilly B, Venugopal D et al. (2013) Optimising assessment intervals improves  
33 visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the  
34 stability phase as a benchmark Graefes Archive for Clinical & Experimental Ophthalmology  
35 251 (10) 2327-2330
- 36 Tufail A, Patel PJ, Egan C et al. (2010) Bevacizumab for neovascular age related macular  
37 degeneration (ABC Trial): multicentre randomised double masked study Bmj 340 c2459-
- 38 Tufail A, Xing W, Johnston R et al. (2014) The neovascular age-related macular  
39 degeneration database: multicenter study of 92 976 ranibizumab injections Ophthalmology  
40 121 (5) 1092-1101
- 41 Vallance JH, Johnson B, Majid MA et al. (2010) A randomised prospective double-masked  
42 exploratory study comparing combination photodynamic treatment and intravitreal  
43 ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-  
44 related macular degeneration Eye 24 1561-1567

- 1 Van dM, A, Sandhu SS et al. (2006) Correlation of optical coherence tomography and fundus  
2 fluorescein angiography following photodynamic therapy for choroidal neovascular  
3 membranes *British Journal of Ophthalmology* 90 (3) 304-306
- 4 van LR, Chakravarthy U, Vingerling JR et al. (2003) Grading of age-related maculopathy for  
5 epidemiological studies: is digital imaging as good as 35-mm film? *Ophthalmology* 110 (8)  
6 1540-1544
- 7 van LR, Boekhoorn S, Vingerling JR et al. (2005) Dietary intake of antioxidants and risk of  
8 age-related macular degeneration *JAMA* 3101-3107
- 9 van V, M E, de S et al. (2006) Added value of OCT in evaluating the presence of leakage in  
10 patients with age-related macular degeneration treated with PDT *Graefes Archive for Clinical  
11 & Experimental Ophthalmology* 244 (9) 1119-1123
- 12 VanderBeek BL, Zacks DN, Talwar N et al. (2011) Racial differences in age-related macular  
13 degeneration rates in the United States: a longitudinal analysis of a managed care network  
14 *American journal of ophthalmology* *Am J Ophthalmol* 273-282
- 15 Varano M, Eter N, Winyard S et al. (2015) Current barriers to treatment for wet age-related  
16 macular degeneration (wAMD): findings from the wAMD patient and caregiver survey *Clinical  
17 Ophthalmology* 9 2243-2250
- 18 Vaze A, Fraser-Bell S, Gillies M (2014) Reasons for discontinuation of intravitreal vascular  
19 endothelial growth factor inhibitors in neovascular age-related macular degeneration *Retina*  
20 34 1774-1778
- 21 Verteporfin In Photodynamic Therapy Study (2001) Verteporfin therapy of subfoveal  
22 choroidal neovascularization in age-related macular degeneration: two-year results of a  
23 randomized clinical trial including lesions with occult with no classic choroidal  
24 neovascularization—verteporfin in photodynamic therapy report 2 *American Journal of  
25 Ophthalmology* 131 (5) 541-560
- 26 Virgili G, Michelessi M, Parodi MB et al. (2015) Laser treatment of drusen to prevent  
27 progression to advanced age-related macular degeneration *The Cochrane Library*
- 28 Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin  
29 therapy of subfoveal minimally classic choroidal neovascularization in age-related macular  
30 degeneration: 2-year results of a randomized clinical trial *Archives of Ophthalmology* 123 (4)  
31 448-
- 32 Vogel RN, Davis DB, Kimura BH et al. (2016) Neovascular age-related macular degeneration  
33 with advanced visual loss treated with anti-vascular endothelial growth factor therapy:  
34 Clinical Outcome and Prognostic Indicators *Retina* no-
- 35 Vottonen P, Kankaanp E (2016) Cost-effectiveness of treating wet age-related macular  
36 degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov  
37 transition model *Acta ophthalmologica* 94 (7) 652-656
- 38 Vukicevic M, Fitzmaurice K (2005) Rehabilitation strategies used to ameliorate the impact of  
39 centre field loss *Visual Impairment Research* 7 79-84
- 40 Vukicevic M, Fitzmaurice K (2009) Eccentric viewing training in the home environment: can it  
41 improve the performance of dynamic self-care activities of daily living? *Journal of visual  
42 impairment & blindness* 103 (5) 277-290
- 43 Vukicevic M, Heraghty J, Cummins R et al. (2016) Caregiver perceptions about the impact of  
44 caring for patients with wet age-related macular degeneration *Eye* 30 (3) 413-421

- 1 Weingessel B, Mihaltz K, Vecsei-Marlovits P, V (2016) Predictors of 1-year visual outcome in  
2 OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in  
3 exudative age-related macular degeneration Wiener Klinische Wochenschrift 128 (15-16)  
4 560-565
- 5 Wilde C, Patel M, Lakshmanan A et al. (2015) The diagnostic accuracy of spectral-domain  
6 optical coherence tomography for neovascular age-related macular degeneration: a  
7 comparison with fundus fluorescein angiography Eye 29 (5) 602-610
- 8 Williams PD, Callanan D, Solley W et al. (2012) A prospective pilot study comparing  
9 combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab  
10 monotherapy in the treatment of neovascular age-related macular degeneration Clinical  
11 ophthalmology (Auckland, N.Z.) 6 1519-1525
- 12 Williams PT (2009) Prospective study of incident age-related macular degeneration in  
13 relation to vigorous physical activity during a 7-year follow-up Investigative ophthalmology  
14 & visual science Invest Ophthalmol Vis Sci 101-106
- 15 Williams TA, Blyth CP (2011) Outcome of ranibizumab treatment in neovascular age related  
16 macula degeneration in eyes with baseline visual acuity better than 6/12 Eye 25 (12) 1617-  
17 1621
- 18 Wilson HL, Schwartz DM, Bhatt HR et al. (2004) Statin and aspirin therapy are associated  
19 with decreased rates of choroidal neovascularization among patients with age-related  
20 macular degeneration American journal of ophthalmology Am J Ophthalmol 615-624
- 21 Wolf-Schnurrbusch UEK, Zinkernagel MS, Munk MR et al. (2015) Oral Lutein  
22 Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in  
23 Combination With Polyunsaturated Fatty Acids PUFA May Lessen Lutein's Effect on MPOD  
24 and CS Investigative ophthalmology & visual science 56 (13) 8069-8074
- 25 Wong T, Chakravarthy U, Klein R et al. (2008) The natural history and prognosis of  
26 neovascular age-related macular degeneration: a systematic review of the literature and  
27 meta-analysis Ophthalmology 115 (1) 116-126
- 28 Wormald R, Evans JR, Smeeth LL et al. (2007) Photodynamic therapy for neovascular  
29 age-related macular degeneration The Cochrane Library
- 30 Writing committee for the UK age-related macular degeneration EMR User group (2014) The  
31 neovascular age-related macular degeneration database: Multicenter study of 92 976  
32 ranibizumab injections: Report 1: Visual acuity manuscript no. 2013-568 Ophthalmology 121  
33 (5) 1092-1101
- 34 Wu B, Li J, Lin H et al. (2016) Different Strategies for the Treatment of Age-Related Macular  
35 Degeneration in China: An Economic Evaluation Journal of ophthalmology 2016
- 36 Wykoff CC, Croft DE, Brown DM et al. (2015) Prospective trial of treat-and-extend versus  
37 monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-Year  
38 Results Ophthalmology 122 (12) 2514-2522
- 39 Yanagi Y, Ueta T, Obata R et al. (2011) Utility values in Japanese patients with exudative  
40 age-related macular degeneration Japanese journal of ophthalmology 55 (1) 35-38
- 41 Yanagi Y, Fukuda A, Barzey V et al. (2016) Cost-effectiveness of intravitreal aflibercept  
42 versus other treatments for wet age-related macular degeneration in Japan Journal of  
43 Medical Economics 1-9
- 44 Ying GS, Huang J, Maguire MG et al. (2013) Baseline predictors for one-year visual  
45 outcomes with ranibizumab or bevacizumab for neovascular age-related macular  
46 degeneration Ophthalmology 120 (1) 122-129

## Macular Degeneration

### Appendix I: References for included and cited studies

- 1 Yonekawa Y, Andreoli C, Miller JB et al. (2013) Conversion to aflibercept for chronic  
2 refractory or recurrent neovascular age-related macular degeneration *Am J Ophthalmol* 156  
3 29-35
- 4 Yuzawa M, Fujita K, Wittrup-Jensen K et al. (2015) Improvement in vision-related function  
5 with intravitreal aflibercept: data from phase 3 studies in wet age-related macular  
6 degeneration *Ophthalmology* 122 (3) 571-578
- 7 Zarranz-Ventura J, Liew G, Johnston RL et al. (2014) The neovascular age-related macular  
8 degeneration database: report 2: incidence, management, and visual outcomes of second  
9 treated eyes *Ophthalmology* 121 (10) 1966-1975
- 10 Zhu M, Chew JK, Broadhead GK et al. (2015) Intravitreal Ranibizumab for neovascular Age-  
11 related macular degeneration in clinical practice: five-year treatment outcomes *Graefes*  
12 *Archive for Clinical & Experimental Ophthalmology* 253 (8) 1217-1225